Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
NCT01474798
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
11
Enrollment
INDUSTRY
Sponsor class
Conditions
Acne Vulgaris
Interventions
DRUG:
RA-18C3
Sponsor
Janssen Research & Development, LLC